The invention relates to a copper contraceptive intrauterine system (IUS) with a flexible frame, which system is further capable of releasing a selective progesterone receptor modulator (SPRM), such as ulipristal acetate, for reducing or preventing bleeding side effects.

The present invention refers to the use of N-acetyl-5-methoxytryptamine (melatonin) and/or an analogue thereof, for use in the medical or veterinary field in the assisted reproduction for promoting the mechanism of implantation of the embryo, and in particular for the prevention of implantation failure into the uterus, by topical administration of an effective amount in a mammalian subject female in need of such treatment, and related compositions, culture media and medical devices.

A pharmaceutical composition contains adipose tissue derived reproductive cells including adipose stem cells, vascular endothelial cells and vascular pericytes. The composition is administrated into an intrauterine cavity of a subject and used for treatment of infertility. A method for producing the pharmaceutical composition includes treating an adipose tissue with a disaggregation agent to obtain a disaggregated tissue; concentrating reproductive cells from the disaggregated tissue by centrifugal separation treatment; and recovering concentrated reproductive cells. A method for treatment of infertility of a subject includes administering a pharmaceutical composition into an intrauterine cavity of a subject. The pharmaceutical composition contains adipose tissue derived reproductive cells including adipose stem cells, vascular endothelial cells and vascular pericytes.

The present disclosure provides methods and compositions comprising a autophagy inhibitors. Also provided herein are autophagy inhibitors for use as a contraceptive device. Also provided are autophagy inhibitors delivered by an intrauterine delivery system (IUS) to prevent pregnancy or provide contraception. Also provided herein are newly identified compositions for use as autophagy inhibitors.

The present invention relates to a method for providing contraception in a female subject, comprising continuous intravaginal administration of levonorgestrel of from about 60 ?g/day to about 100 ?g/day. The invention further relates to a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and/or dysmenorrhea comprising continuously administering about 60 ?g/day to about 160 ?g/day of levonorgestrel. Delivery devices, such as, intravaginal rings for putting the methods in practice are also envisaged.

The present invention relates to a method for providing contraception in a female subject, comprising continuous intravaginal administration of levonorgestrel of from about 60 ?g/day to about 100 ?g/day. The invention further relates to a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and/or dysmenorrhea comprising continuously administering about 60 ?g/day to about 160 ?g/day of levonorgestrel. Delivery devices, such as, intravaginal rings for putting the methods in practice are also envisaged.

The invention relates to a method for contraception and for reducing menstrual problems and inducing amcnorrhca, whcrcin an intrauterine delivery device is used for the controlled release of a combination of progestogen or a drug having a progestogenic activity and at least one therapeutically active substance capable of preventing or suppressing abnormal and/or irregular endometrial bleeding over a prolonged period of time.

The present invention refers to the use of N-acetyl-5-methoxytryptamine (melatonin) and/or an analog thereof, for use in the medical or veterinary field in the assisted reproduction for promoting the mechanism of implantation of the embryo, and in particular for the prevention of implantation failure into the uterus, by topical administration of an effective amount in a mammalian subject female in need of such treatment, and related compositions, culture media and medical devices.

An intrauterine contraceptive system may include a contraceptive intrauterine device, a retrieval thread permanently attached to the intrauterine device and an insertion device for inserting the intrauterine device into a uterus. The system may also include a release thread releasably coupled with the intrauterine device. The intrauterine device may be deployable out of a distal end of the insertion device and may be configured to change from a delivery configuration when housed in the insertion device to a deployed configuration when deployed in a uterus. The retrieval thread and the optional release thread may be at least partially housed within the insertion device during insertion of the intrauterine device into the uterus. The release thread may extend from the intrauterine device through the insertion device to an attachment point at or near a proximal end of the insertion device.

The invention relates to a method for contraception and for reducing menstrual problems and inducing amenorrhea, wherein an intrauterine delivery device is used for the controlled release of a combination of progestogen or a drug having a progestogenic activity and at least one therapeutically active substance capable of preventing or suppressing abnormal and/or irregular endometrial bleeding over a prolonged period of time.